Walleye Capital’s Quest Diagnostics DGX Stock Holding History

Walleye Capital’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$435K	Sell	2,218 -13,861	-86%	-$2.69M	﹤0.01%	2772
2025 Q4	$2.79M	Buy	16,079 +16,001	+20,514%	+$2.91M	0.01%	1592
2025 Q3	$14.9K	Sell	78 -130	-63%	-$23.1K	﹤0.01%	4240
2025 Q2	$37.4K	Sell	208 -133	-39%	-$23.1K	﹤0.01%	4120
2025 Q1	$57.7K	Sell	341 -3,399	-91%	-$558K	﹤0.01%	3805
2024 Q4	$564K	Buy	3,740 +1,479	+65%	+$230K	﹤0.01%	2887
2024 Q3	$351K	Sell	2,261 -14,708	-87%	-$2.2M	﹤0.01%	3605
2024 Q2	$2.32M	Buy	16,969 +10,423	+159%	+$1.43M	﹤0.01%	1964
2024 Q1	$871K	Buy	+6,546	New	+$849K	﹤0.01%	2724
2019 Q4	–	Sell	-260	Closed	-$28K	–	1889
2019 Q3	$28K	Hold	260	–	–	﹤0.01%	1695
2019 Q2	$26K	Buy	+260	New	+$25K	﹤0.01%	1491

Other funds holding DGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Walleye Capital's DGX Position: Q1 2026 in Review

Walleye Capital reduced its Quest Diagnostics (DGX) stake by 86% in Q1 2026, selling an estimated $2.69M and leaving 2,218 shares worth $435K. The position accounts for ﹤0.01% of the portfolio, ranked #2772.

Walleye Capital first reported a position in DGX in Q2 2019 and has held it in 11 quarters since. The position peaked at $2.79M in Q4 2025. 1,065 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

Walleye Capital held 2,218 shares of Quest Diagnostics worth $435K as of Q1 2026.
Walleye Capital sold 13,861 Quest Diagnostics shares in Q1 2026, an estimated $2.69M.
Quest Diagnostics made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #2772 holding.
Walleye Capital first reported a position in Quest Diagnostics in Q2 2019 and has held it in 11 quarters since.
Walleye Capital's Quest Diagnostics position peaked at $2.79M in Q4 2025.
1,065 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.